Humira use in pJIA extended

The licence for Humira (adalimumab) in polyarticular juvenile idiopathic arthritis (pJIA) has been extended to include the treatment of children from 4 years-old. Humira can be given in combination with methotrexate when the response to one or more DMARDs is inadequate, or as monotherapy if methotrexate is inappropriate or not tolerated.

The recommended dose is 24mg/m2 (max 40mg) by subcutaneous injection every other week. To enable accurate dosing, Humira solution for injection is now available as a vial, in addition to the prefilled pen and syringe presentations.

View Humira drug record

Further Information: Abbott Laboratories Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Antidiabetic Agents, Use in Renal Impairment

Antidiabetic Agents, Use in Renal Impairment

Dosing of diabetes drugs in patients with renal impairment.

Insulin Delivery Devices

Insulin Delivery Devices

Features and compatibility of insulin pens.

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.